Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Q4 FY26 Earnings Presentation
25 slides from Akums Drugs And Pharmaceuticals's earnings presentation, May 14, 2026
Slide 1: Exchange disclosure cover letter under Regulation 30
Ref: Akums/Exchange/2026-27/12 May 14, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Jeejeebhoy Bandra Kurla Complex, Towers, Dalal Street, Fort, Mumbai – Bandra (E),Mumbai – 400 051
Slide 2: Q4 and FY 25-26 Investor Presentation
Q4 and FY 25-26 Investor Presentation May 2026
Slide 3: Disclaimer
Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The co
Slide 4: Managing Directors’ Message
Managing Directors’ Message Dear Investors We are pleased to announce the results for Q4 FY26 as well as full year FY26. During Q4 FY26, we maintained the business momentum of last quarter and ended FY26 on a strong note despite a very challenging H1 FY26. The operating environment through the first
Slide 5: More than Two Decades’ Legacy of Expertise, Experience & Trust
More than Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Acquired Established R&D lab in Mumbai to Parabolic Drugs to manufacturing site for Launched Akumentis to venture into regul
Slide 6: Technologically Advanced Manufacturing Capabilities
Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 264 6 269 2.635 732 17 392 41 Ayurvedic / β-lac
Slide 7: R&D Focus
R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 6
Slide 8: Key drivers as well as their trends during FY26
Key drivers as well as their trends during FY26 Key drivers and their impact on Akums’ performance API prices Strong volume Operating Trade generics remained soft growth, despite leverage and turnaround but though initial muted volumes ramp up of new API losses signs of in the IPM facilities continu
Slide 9: Key highlights of FY26
Key highlights of FY26 • Product Development completed in H1 FY26 200 Mn Euro CDMO contract progressing • EU GMP approval for plant 2 received in Q3 FY26 as per timelines • Dossier filling on track with supplies starting FY28 onwards • Total project cost ~.USD 45 million, with Akums owning 51% stake
Slide 10: Financial Performance Highlights
Q4 FY 26 and FY 25-26 Financial Performance Highlights 9
Slide 11: Q4FY26 Performance Highlights
Q4FY26 Performance Highlights Consolidated Performance Segment Break-up Share in Q4 FY26 187 cr 81 cr Business Vertical revenue 1,193 cr 121 cr 54 cr 1,050 cr 15.7% 6.8% CDMO 82.2% 11.6% 5.1% Domestic Branded Total Income EBITDA PAT 8.8% Formulation Total Income (+11.2% YoY) Adj. EBITDA (+67.8% YoY)
Slide 12: FY26 Performance Highlights
FY26 Performance Highlights Consolidated Performance Segment Break-up Share in FY26 651 cr 256 cr Business Vertical revenue 4,488 cr 121 cr 54 cr 1,050 cr 14.5% 5.7% CDMO 80.0% 11.6% 5.1% Domestic Branded Total Income EBITDA PAT 10.2% Formulation Total Income (+7.6% YoY) Adj. EBITDA (+26.9%* YoY) (-
Slide 13: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs Cr) Q4 FY26 Q4 FY25 Y-O-Y (%) Q3 FY26 Q-O-Q (%) FY26 FY25 Y-O-Y (%) Revenue 1,158 1,056 9.7% 1,160 (0.1)% 4,359 4,118 5.8% COGS 660 639 3.3% 679 (2.7)% 2,514 2,433 3.3% GP Margin % 43.0% 39.5% 41.5% 42.3% 40.9% Employee Expenses 199 184 8.2% 189 5.1% 754 716
Slide 14: Quarterly Performance Trends
Quarterly Performance Trends Revenue (INR Cr.) Adjusted EBITDA (INR Cr) Adjusted PAT (INR Cr) Margin % Margin % 8.9% 12.6% 9.3% 12.7% 13.1% 3.3% 6.2% 4.1% 7.2% 7.0% 9.7% 61.6% 134.9 % 1,160 1,158 1,056 86 83 1,024 1,018 147 152 129 65 94 94 43 35 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q4 FY25 Q1 FY
Slide 15: Annual Performance Trends
Annual Performance Trends Revenue (INR Cr.) Adjusted EBITDA (INR Cr) Adjusted PAT (INR Cr) Margin % Margin % 11.2% 12.0% 5.2% 6.2% 5.8% 13.3% 27.3% 4,359 4,118 522 276 461 217 FY25 FY26 FY25 FY26 FY25 FY26 14
Slide 16: Annual Performance Highlights
Annual Performance Highlights Working Capital (Days) Operating Cash Flow (INR Cr) Return Ratios Adj OCF/EBITDA %* Net WC 91 105 90.7% 34.9% Adj ROE Debtors ROCE Adj ROIC Creditors 110 465 14.6%14.3% Inventory 102 11.7% 80 68 67 71 8.4% 8.3% 227 7.1% FY 25 FY 26 FY 25 FY 26 FY 25 FY 26 *Excluding fai
Slide 17: Revenue and Margin Deep-Dive – Quarterly
Revenue and Margin Deep-Dive – Quarterly Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) • Revenue growth driven by CDMO • Other exp and employee expenses benefitted • Strong double digit volume growth driving from operating leverage revenues • Price variance largely flat though product mix im
Slide 18: Revenue and Margin Deep-Dive – Annual
Revenue and Margin Deep-Dive – Annual Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) • Revenue growth driven by improved volumes • Other expenses increased due to higher • Volumes grew despite muted volumes in the in CDMO power and fuel expenses IPM • Erosion in API prices and consolidation i
Slide 19: Segmental Quarterly Performance
Segmental Quarterly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue QoQ 4.0% YoY 13.4% QoQ -11.1% YoY -1.5% QoQ -28.5% YoY -9.7% QoQ 10.2% YoY 22.6% QoQ -24.9% YoY -18.8% 25 27 54 952 115 50 50 104 102 22 41 9
Slide 20: Segmental Annual Performance
Segmental Annual Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue YoY 8.6% YoY 2.9% YoY 0.6% YoY -13.2% YoY -15.9% 3,485 3,208 446 143 143 219 434 115 100 184 FY25 FY26 FY25 FY26 FY25 FY26 FY25 FY26 FY25 FY26 D
Slide 21: Key Growth Drivers
Key Growth Drivers Multi-year European CDMO contract to enhance growth visibility - Supplies for EU CDMO contract expected to commence from FY28 with commitments for at least 5 more years Zambia – annual supplies and manufacturing plant, to aid global expansion – USD 25 million per year supply commi
Slide 22: Objects of the offer
Objects of the offer Amount as per offer Utilization as on March Objects (INR Cr) Unutilized Amount document* 31, 2026 Repayment borrowings of Akums 159.91 159.91 - Repayment of borrowings of our 227.09 227.09 - Subsidiaries Funding incremental working capital 55.00 55.00 - requirements of our Compa
Slide 23: Annexures
Annexures ‘bel lids
Slide 24: Abbreviations and Definitions
Abbreviations and Definitions Abbreviations Definitions • CDMO: Contract development and manufacturing organization • Adj EBITDA: Profit before tax + fair value changes to • API: Active Pharmaceutical Ingredient financial instrument + finance cost + depreciation and amortization + Exceptional items
Slide 25: Thank You
Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net Siddharth Rangnekar / Shruti Joshi CDR, India Tel: +91 97699 19966 / 75065 67349 Email: siddharth@cdr-india.com / shruti@cdr-india.com 24
Akums Drugs and Pharmaceuticals — Q4 FY26 Earnings Presentation on 6ix